Biopharma Services
End-to-end drug development support from discovery to commercialization
Service · OtherCompany source
Company profile
About Foundation Medicine
Foundation Medicine offers comprehensive genomic profiling to help match cancer patients with targeted therapies and immunotherapies.
Company description Foundation Medicine official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Work at Foundation Medicine?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Advanced cancer
- Early stage breast cancer
- Hematologic malignancies
- Lung cancer
- Melanoma
- Sarcomas
- Solid tumors
Who it serves
- Biopharma companies
- Cancer care networks
- Health systems
- Healthcare providers
- Oncologists
- Pathology laboratories
- Patients
- Research institutions
Deployment & integration
Cloud Saas · Other deployment with recorded integration context.
Recorded integration context: EMR systems (all EMRs mentioned), Pathology Portal.
Geographic context
MarketsGlobal (implied through biopharma partnerships) · United States
Company sourceOfficial website
Company milestones
Platform expansion
FoundationOne CDx approved as first CGP test with group-based companion diagnostic claim for BRAF inhibitors in melanoma (2021-2022). FoundationOne RNA launched for combined DNA + RNA fusion detection. FoundationOne MRD introduced for early stage breast cancer (2025).
Partnerships
Recorded partners
- Biopharma partners for drug development
- Cancer care networks
- Health systems
- Pathology laboratories
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
FoundationOne CDx
FDA-approved tissue-based broad companion diagnostic for all solid tumors
Software · OtherCompany source
FoundationOne Heme
Laboratory developed test for hematologic malignancies and sarcomas
Software · OtherCompany source
FoundationOne Liquid CDx
FDA-approved blood-based companion diagnostic for all solid tumors
Software · OtherCompany source
FoundationOne MRD
Minimal residual disease detection for early stage breast cancer
Software · OtherCompany source
FoundationOne PGx
Pharmacogenomic testing for personalized medication management
Software · OtherCompany source
FoundationOne RNA
Combined DNA + RNA fusion detection for comprehensive genomic profiling
Software · OtherCompany source
Germline Testing
Hereditary cancer risk assessment through germline genetic testing
Software · OtherCompany source
IHC Testing
Immunohistochemistry testing for protein expression analysis
Software · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Nucleoporin 98 Rearrangements in Acute Leukemia: A Genomic Landscape Study.Hematological oncology · Sep 1, 2026
Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project.The journal of liquid biopsy · Sep 1, 2026
Clinical, genomic, and spatial transcriptomic features of pancreatic adenosquamous carcinoma support subtype-specific therapeutic strategies.Clinical cancer research : an official journal of the American Association for Cancer Research · Aug 14, 2026
SPEN inactivation drives resistance to androgen receptor pathway inhibitors in metastatic prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · Aug 13, 2026
Genomic Landscape and Therapeutic Implications of ALK Fusion-Positive Colorectal Cancer.The oncologist · Aug 7, 2026
Single-cohort next-generation sequencing analysis of 713 anaplastic thyroid carcinomas: unreported gene alterations and actionable targets.American journal of clinical pathology · Aug 4, 2026
Clinical validation
Clinical-trial records
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal AdenocarcinomaNCT06141031 · Sponsor · RECRUITING
Spontaneous Antigenemia in LoiasisNCT04258670 · Sponsor · COMPLETED
A Novel Digital Music-based Autonomous Personalized Walking Intervention to Improve Gait and Walking Automaticity in Parkinson DiseaseNCT07705373 · Sponsor · RECRUITING
Xylitol and the Prevention of Periodontal Disease and Preterm Birth TrialNCT07424846 · Sponsor · RECRUITING
CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for AsthmaNCT07241117 · Sponsor · RECRUITING
CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIVNCT07090174 · Sponsor · WITHDRAWN
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Over 1.5 million patient CGP reports delivered
Clinical impact and scale
More than 50% of all approved US CDx indications for NGS testing
Market leadership in companion diagnostics
2,400+ research publications
Scientific evidence base
35+ targeted therapy indications for FoundationOne CDx
Therapeutic matching capability
15+ targeted therapy indications for FoundationOne Liquid CDx
Blood-based diagnostic utility
Summer (Patient)
Stage IV lung cancer diagnosis and treatment planning
ALK mutation identified enabling personalized treatment plan for stage IV lung cancer
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Jason Adams
Vice President, Head of Biopharma Business Development
Mikael Barmore
Vice President of Clinical Commercial Marketing
Andrea Marengi
Vice President, Deputy General Counsel
Ian Ide
Vice President Talent Acquisition
Winnie Swan
Senior Vice President, Secretary, General Counsel and Chief Compliance Officer
Marcus Thompson, MBA
Vice President of Sales
Dominique Schutz
CFO & Head of Corporate Management
Ronak Shah
Tech Lead
06 · Company updates
Updates from Foundation Medicine
Recent articles published on Foundation Medicine's official website.
A New Era of Precision Medicine for Childhood Cancer
Read on Foundation MedicineA Milestone in Advancing Cancer Care: 1,000 Peer-Reviewed Publications and Counting
Read on Foundation MedicineA High-Quality Testing Portfolio Grounded in Science – A Research Recap
Read on Foundation MedicineUshering in a New Era of Personalized Treatment for Advanced Prostate Cancer
Read on Foundation MedicineForging Forward - Our Progress in Biopharmaceutical Partnerships and Outlook for Success in 2025
Read on Foundation Medicine07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.